Correlation Between Oncorus and Unicycive Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Oncorus and Unicycive Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Oncorus and Unicycive Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Oncorus and Unicycive Therapeutics, you can compare the effects of market volatilities on Oncorus and Unicycive Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Oncorus with a short position of Unicycive Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Oncorus and Unicycive Therapeutics.

Diversification Opportunities for Oncorus and Unicycive Therapeutics

-0.81
  Correlation Coefficient

Pay attention - limited upside

The 3 months correlation between Oncorus and Unicycive is -0.81. Overlapping area represents the amount of risk that can be diversified away by holding Oncorus and Unicycive Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Unicycive Therapeutics and Oncorus is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Oncorus are associated (or correlated) with Unicycive Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Unicycive Therapeutics has no effect on the direction of Oncorus i.e., Oncorus and Unicycive Therapeutics go up and down completely randomly.

Pair Corralation between Oncorus and Unicycive Therapeutics

If you would invest  33.00  in Unicycive Therapeutics on August 28, 2024 and sell it today you would earn a total of  22.00  from holding Unicycive Therapeutics or generate 66.67% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthSignificant
Accuracy1.59%
ValuesDaily Returns

Oncorus  vs.  Unicycive Therapeutics

 Performance 
       Timeline  
Oncorus 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Oncorus has generated negative risk-adjusted returns adding no value to investors with long positions. Even with relatively invariable fundamental indicators, Oncorus is not utilizing all of its potentials. The current stock price agitation, may contribute to short-term losses for the retail investors.
Unicycive Therapeutics 

Risk-Adjusted Performance

14 of 100

 
Weak
 
Strong
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Unicycive Therapeutics are ranked lower than 14 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak fundamental indicators, Unicycive Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point.

Oncorus and Unicycive Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Oncorus and Unicycive Therapeutics

The main advantage of trading using opposite Oncorus and Unicycive Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Oncorus position performs unexpectedly, Unicycive Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Unicycive Therapeutics will offset losses from the drop in Unicycive Therapeutics' long position.
The idea behind Oncorus and Unicycive Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.

Other Complementary Tools

Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities